Articles tagged with Sarcoma
Researchers at Georgetown University Medical Center used a novel approach to find that the FDA-approved drug clofarabine can shut down Ewing sarcoma cells in lab tests. The study suggests that clofarabine may be effective in treating this rare and aggressive cancer, which primarily affects young people.
Cancer researchers have identified CDK12 inhibitors as a potential treatment option for Ewing sarcoma, a rare and aggressive childhood cancer. The inhibitors show promise in killing Ewing sarcoma cells and can be combined with PARP inhibitors to increase effectiveness. This breakthrough brings hope to the pediatric oncology field, whic...
The study tested a new combination of gemcitabine and sirolimus in patients with sarcomas, showing a 44% rate of patients free of progression at 3 months. Researchers believe the treatment's positive results warrant further evaluation in subsequent studies.
The Phase II study demonstrated an overall response rate of 60%, including partial responses in 12% and stabilization of the disease in 48% of cases. Median progression-free survival was also achieved at 3 months, with manageable adverse effects related to myelosuppression.
Researchers characterized two classes of GGAA-microsatellites that interact with EWS/FLI binding sites, revealing unique regulatory mechanisms for cancer susceptibility and treatment
Researchers at Georgetown University Medical Center discovered a novel agent YK-4-279 that, when combined with vincristine, halts the ability of Ewing sarcoma to grow and progress. The combination produces a microtubule catastrophe in cancer cells, targeting their ability to divide and multiply.
New research suggests that male hormones promote infection with the virus that causes Kaposi's sarcoma, a type of cancer. The study found that androgen receptors in cells are activated by male hormones, leading to increased levels of KSHV genetic material detected in infected men.
F8-TNF stimulates killer cells to target sarcomas by identifying them through dormant viral proteins, offering a new avenue for cancer immunotherapy. The treatment has been shown to completely cure mice of sarcoma and grant immune protection against tumor recurrence.
A novel sarcoma vaccine has shown an escalating immune response in patients, indicating its potential anti-cancer effects. The findings suggest that the vaccine can generate an immune response and stabilize tumors, making it a promising treatment option.
Researchers create a cellular model of Ewing sarcoma in human stem cells using CRISPR technology, enabling the study of mechanisms underlying the disease. The technique improves upon previous methods, increasing success rates by up to seven-fold and opening new avenues for cancer research and potential treatment.
Researchers found that projecting videos onto the inside of a radiotherapy machine reduced the need for general anesthesia in children with cancer, making treatment less traumatic and more efficient. The study used video projection to calm anxious kids and save time, resulting in faster treatment times and reduced stress.
Researchers have identified two sarcoma subtypes, leiomyosarcoma and pleomorphic, as likely susceptible to immunotherapy. The study analyzed 81 patient samples, revealing patterns of immune response that suggest these subtypes can be targeted with checkpoint inhibitors.
A recent Phase 1 trial found that an experimental drug called G100 triggered a heightened immune response in tumors, causing them to stop growing or shrink in 14 out of 15 patients. The treatment, which is based on a bacterial molecule, may represent a promising way to induce localized immune responses against cancer.
A University of Colorado Cancer Center study found that knocking down the Jumonji protein KDM3A inhibits Ewing's Sarcoma metastasis. The researchers also discovered another protein, Melanoma Cell Adhesion Molecule (MCAM), plays a crucial role in the cancer's spread.
Researchers found that the activated S6 ribosomal protein P-S6S240 was present in 32% of high-grade tumors and associated with shorter progression-free survival. PI3K/mTOR inhibitors showed promising results in two patient-derived xenograft models, suggesting a potential treatment option for patients with this type of uterine sarcoma.
Researchers report a high success rate for a regional chemotherapy technique that preserves limbs in patients with advanced soft tissue sarcomas. The study found that nearly 80 percent of patients were able to avoid amputation using the technique, known as isolated limb perfusion.
Researchers found that Ewing sarcoma tumors display unique DNA methylation patterns, which influence gene activity and can lead to different outcomes. The study's results provide insights into the biology of Ewing sarcoma and may lead to personalized therapies with fewer side effects.
Researchers present first data on rare sarcomas in Asian patients, showing poor overall survival rates. Chemotherapy improves survival in advanced cases, but treatment rates remain low, with physician-related factors possibly at play.
A 69-year-old Vietnam war veteran was diagnosed with pleomorphic liposarcoma, a rare type of cancer, after exposure to Agent Orange during his service. The patient's cancer has a high rate of local recurrence and ability to spread to other parts of the body, making early detection crucial.
A new anti-cancer drug, GDC-0575, has shown remarkable effectiveness when combined with gemcitabine in treating advanced soft tissue sarcomas. The combination significantly reduced tumour growth rate and led to long-lasting periods without disease progression in two patients.
Scientists at UNC Lineberger Comprehensive Cancer Center found that certain short, repetitive DNA sequences contribute to the development of Ewing sarcoma by enhancing susceptibility to an oncoprotein. These sequences interact with histones in a way similar to stem cells, allowing the oncoprotein to change gene expression.
Researchers at Indiana University have discovered a connection between the genetic mechanisms that trigger Ewing's sarcoma and prostate cancer. This finding could lead to the development of new treatments for patients with both diseases.
A multi-center study found significant survival gains in patients with high-risk soft tissue sarcoma of the trunk or extremities treated with neoadjuvant chemotherapy with an anthracycline plus ifosfamide. The regimen showed a 20% improvement in prognosis for these patients compared to those receiving histology-driven regimens.
PharmaMar presents updated clinical trial data for its antitumoral compounds Yondelis and lurbinectedin, demonstrating efficacy in treating solid tumors such as breast, soft tissue sarcomas, and colorectal cancer. These findings support the potential of these molecules as treatments for various types of solid tumors.
A new orthotopic animal model has been created to study metastasis in Ewing sarcoma, allowing researchers to replicate the primary tumor's growth environment. The model provides valuable insights into metastatic processes and may become a tool for analyzing metastatic potential in other sarcomas.
A landmark study published in The Lancet Oncology reveals new genetic risk factors for sarcoma, a disproportionate cause of disease-related death among children and young adults in Australia. Carrying two or more of these rare mutations increases an individual's cancer risk.
A phase 2 clinical trial found that adding olaratumab to doxorubicin increased median overall survival by nearly a year in patients with advanced sarcoma. The combination therapy showed no significant increase in treatment side effects.
Researchers have identified neurotrophin signaling proteins as promising therapeutic targets and biomarkers for childhood cancers. These proteins, including BDNF and NGF, can inhibit tumor growth and make cancer cells more susceptible to chemotherapy, offering new hope for improved treatment outcomes.
Researchers from Memorial Sloan Kettering Cancer Center share results of experience with over 500 patients with pulmonary metastases from STS, identifying prognostic factors associated with improved survival. The study found that leiomyosarcoma histologic subtype, primary tumor size, and minimally invasive resections were significantly...
Researchers have identified two new compounds that show promise in treating Ewing sarcoma, a rare and aggressive form of childhood cancer. The compounds target the transcription factor EWS-FLI1, which plays a key role in gene regulation, leading to uncontrolled cellular proliferation and tumors.
A large prospective post-commercialization study in patients with advanced soft tissue sarcoma (STS) in Europe confirms the long-term anticancer activity of YONDELIS® (trabectedin). The median progression-free survival was 5.5 months, and durable responses were observed in 18 patients still on treatment.
PharmaMar presents new data for YONDELIS (trabectedin) in soft tissue sarcoma and solid tumors, including final overall survival analysis and real-world data from a large prospective phase IV study. Additionally, early clinical studies show synergistic activity for PM1183 in combination with paclitaxel or cisplatin.
The EORTC will present on precision medicine, including a discussion of molecular subgroups and randomized trials. The organization will also focus on survivorship care, exploring the importance of long-term follow-up and evidence-based approaches.
Researchers from Ludwig-Maximilians-Universität München elucidated the molecular level interactions between an inherited mutation and a spontaneous somatic mutation in Ewing's sarcoma. The team discovered that a germline susceptibility variant increases risk for the disease by interacting with a driver mutation, promoting tumorigenesis.
Researchers have found a potential treatment option for children with Ewing's sarcoma by combining two active ingredients, Olaparib and Trabectedin, which achieves complete remission in all cases. The combination enhances the sensitivity of cancer cells to these drugs, increasing its effect.
Results from the EORTC trial 62072 show pazopanib improves progression-free survival in soft tissue sarcoma patients without affecting their health-related quality of life. The study provides valuable data on treatment outcomes and cost effectiveness for this patient population.
PharmaMar presents clinical studies showcasing the efficacy of YONDELIS and PM1183 in treating small cell lung cancer, soft tissue sarcoma, and malignant pleural mesothelioma. The studies demonstrate promising results with a response rate of 67% for PM1183 in SCLC.
A large retrospective study of 885 patients with soft-tissue sarcoma found that YONDELIS treatment was effective, with median progression-free survival and overall survival of 4.4 and 12.2 months, respectively. Early administration as second-line therapy may optimize efficacy.
A large-scale study found a 0.22% incidence of uterine sarcoma in women after hysterectomy, with most cases being unexpected endometrial cancer. Researchers emphasized the need to balance minimally-invasive procedures with cautious preoperative planning.
A study in Lancet Oncology suggests continued treatment with YONDELIS for advanced soft-tissue sarcoma patients who have not progressed after six courses improves progression-free survival. The results also indicate that a drug holiday may worsen outcomes.
A new standard of care for soft tissue sarcomas has been established through a study that shows image-guided radiotherapy can reduce long-term side effects while maintaining survival rates. The treatment delivers smaller radiation doses to tumors, minimizing exposure to surrounding healthy tissue.
A University of Colorado study finds alterations in expression of PIK3R3 and PTEN genes in young-adult Ewing Sarcoma, commonly observed in adult tumors. These findings could lead to adapted therapeutic strategies for adult cancers to treat Ewing Sarcoma.
Researchers suggest inhibition of Sirtuin1 protein as a future treatment option for metastatic Ewing sarcoma. The study found overexpression of sirtuin 1 significantly correlated with metastasis in patient samples, opening the door to treatment of aggressive tumors.
A genetic abnormality drives Ewing sarcoma through two processes: stimulating tumor growth and suppressing cancer development. New therapies may target these mechanisms.
A new study identifies Ewing sarcoma-associated transcript 1 (EWSAT1) as a critical target of the EWS-FLI1 fusion protein, contributing to cancer cell growth and repression of key genes. This finding supports the notion that long noncoding RNAs can drive cancer development and highlights an important mediator in Ewing Sarcoma.
Researchers at IDIBELL and ICO have tested a new therapeutic combination of conventional chemotherapy and rapamycin to combat resistant sarcomas. The Phase I trial showed promising results, with the tumor stopping growth and not recovering after treatment, and has launched a Phase II clinical trial.
A phase I clinical trial found that ex vivo cultured cord blood stem cells showed improved engraftment rates and earlier hematopoietic recovery in patients with hematological malignancies. The study also developed a murine model of Ewing's sarcoma, revealing tumor origins in embryonic osteochondrogenic progenitors.
The EORTC trial 62012 found that adding ifosfamide to doxorubicin improved median progression-free survival, but not overall survival or tumor shrinkage, in advanced soft tissue sarcoma patients. Combination chemotherapy also resulted in more overall responses compared to doxorubicin alone.
EORTC analysis confirms performance status, tumor grading, and hemoglobin levels as key predictors of long-term outcomes in pazopanib-treated patients. Long-term responders and survivors accounted for 36% and 34% of patients respectively.
Researchers identified microRNA-22 as a key player in Ewing's Sarcoma, regulating KDM3A gene expression. Targeting KDM3A with small-molecule inhibitors may provide new therapeutic options for the disease.
The EORTC-ESTRO joint session will present the latest research on soft tissue sarcoma treatment, emphasizing the importance of early patient management. Key experts will discuss optimal timing sequences for radiotherapy in limb and retroperitoneal sarcomas, as well as current concepts in chordoma management.
Researchers at Huntsman Cancer Institute are testing a novel targeted treatment for Ewing sarcoma, which has spread by the time it's diagnosed. The goal is to disrupt cancer growth and spread using LSD1 inhibitors, with preclinical trials underway.
A LSUHSC study found significant racial and ethnic disparities in the incidence of soft tissue sarcomas among adolescents and young adults. The research revealed that African-American and Hispanic males were more likely to develop certain types of cancer, such as Kaposi sarcoma and liposarcoma.
Researchers at Ohio State University Comprehensive Cancer Center discovered that the tumor-suppressor gene A20 is silenced due to the loss of microRNA-29, leading to increased levels of NF-kB and tumor progression. This finding could guide the development of more effective therapies for soft-tissue sarcomas.
A recent study found that orthopedic oncologists and surgical oncologists conducted only 52% of sarcoma surgeries, while general surgeons, plastic surgeons, and orthopedic surgeons performed the remaining 48%. This disparity may impact patient outcomes due to varying levels of expertise in removing deep-seated tumors.
Cornell University engineers have developed a new smartphone-based system for in-the-field detection of Kaposi's sarcoma and other conditions, utilizing a plug-in optical sensor and disposable microfluidic chips. This novel technique provides a quick method to quantify viral DNA levels, requiring minimal training and expertise.
The EORTC 62024 trial found that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/intermediate-risk GIST. The trial showed a non-statistically significant trend in favor of the adjuvant arm for Imatinib failure-free survival.
Researchers at UCLA's Jonsson Comprehensive Center have identified liposarcoma tumors that can be imaged by PET scanning using a tracer substance known as FAC, and found these tumors are sensitive to chemotherapy. This discovery has translational potential for liposarcoma patients and may lead to more effective treatment strategies.
Researchers at Huntsman Cancer Institute have discovered a new drug with high potential to treat Ewing sarcoma by targeting the EWS/FLI protein. The study found that an enzyme called lysine specific demethylase (LSD-1) interacts with EWS/FLI to turn off gene expression in Ewing sarcoma.
Researchers found that blocking galectin-1 in mice with established Kaposi sarcomas slowed tumor growth by suppressing blood vessel formation. This breakthrough holds promise for new treatment options for patients with KS and may also be effective for other diseases characterized by aberrant blood vessel growth.